Reprieve FASTR II Trial

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

This study aims to prospectively compare the safety, effectiveness, and clinical utility of decongestive therapy administered by the Reprieve System to optimal diuretic therapy in adult ADHF patients presenting to the ED requiring decongestion. The Reprieve System continuously monitors urine output and urine sodium concentration to identify and administer the diuretic dose required to meet decongestion goals (max 72hr).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 02 Apr 2026. Study ID: 25-0919
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research